Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascale Tomasini

Showing results (11-20 of 95) with videos related to

Pageof 10
Sort By:
Translational Lung Cancer Research|May 19, 2020
Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?Camille Travert, Pascale Tomasini, Fabrice Barlesi
Bulletin Du Cancer|March 28, 2025
[Recommendations for the management of oligometatic NSCLC]Alice Mogenet, Laurent Greillier, Pascale Tomasini
European Respiratory Review : an Official Journal of the European Respiratory Society|November 17, 2017
Personalised medicine for nonsmall cell lung cancerCéline Mascaux, Pascale Tomasini, Laurent Greillier, et al.
Bulletin Du Cancer|September 26, 2020
[Predictable toxicities with futures immunotherapies or combinations]Alice Mogenet, Pascale Tomasini, Laurent Greillier, et al.
Expert Review of Anticancer Therapy|March 13, 2013
The place of pemetrexed in the management of non-small-cell lung cancer patientsPascale Tomasini, Laurent Greillier, Nataliya Khobta, et al.
Translational Lung Cancer Research|February 11, 2020
Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?Alice Mogenet, Pascale Tomasini, Laurent Greillier, et al.
Therapeutic Advances in Medical Oncology|May 31, 2016
Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomesPascale Tomasini, Fabrice Barlesi, Celine Mascaux, et al.
Therapeutic Advances in Medical Oncology|March 17, 2012
Ipilimumab: its potential in non-small cell lung cancerPascale Tomasini, Nataliya Khobta, Laurent Greillier, et al.
Current Oncology Reports|August 18, 2020
Immune Oncology Biomarkers in Lung Cancer: an OverviewCamille Travert, Fabrice Barlesi, Laurent Greillier, et al.
Journal of Thoracic Disease|June 1, 2018
Durvalumab after chemoradiotherapy in stage III non-small cell lung cancerPascale Tomasini, Laurent Greillier, Arnaud Boyer, et al.
Pageof 10

Showing results (11-20 of 95) with videos related to

Sort By:
Pageof 10
Translational Lung Cancer Research|May 19, 2020
Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?Camille Travert, Pascale Tomasini, Fabrice Barlesi
Bulletin Du Cancer|March 28, 2025
[Recommendations for the management of oligometatic NSCLC]Alice Mogenet, Laurent Greillier, Pascale Tomasini
European Respiratory Review : an Official Journal of the European Respiratory Society|November 17, 2017
Personalised medicine for nonsmall cell lung cancerCéline Mascaux, Pascale Tomasini, Laurent Greillier, et al.
Bulletin Du Cancer|September 26, 2020
[Predictable toxicities with futures immunotherapies or combinations]Alice Mogenet, Pascale Tomasini, Laurent Greillier, et al.
Expert Review of Anticancer Therapy|March 13, 2013
The place of pemetrexed in the management of non-small-cell lung cancer patientsPascale Tomasini, Laurent Greillier, Nataliya Khobta, et al.
Translational Lung Cancer Research|February 11, 2020
Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?Alice Mogenet, Pascale Tomasini, Laurent Greillier, et al.
Therapeutic Advances in Medical Oncology|May 31, 2016
Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomesPascale Tomasini, Fabrice Barlesi, Celine Mascaux, et al.
Therapeutic Advances in Medical Oncology|March 17, 2012
Ipilimumab: its potential in non-small cell lung cancerPascale Tomasini, Nataliya Khobta, Laurent Greillier, et al.
Current Oncology Reports|August 18, 2020
Immune Oncology Biomarkers in Lung Cancer: an OverviewCamille Travert, Fabrice Barlesi, Laurent Greillier, et al.
Journal of Thoracic Disease|June 1, 2018
Durvalumab after chemoradiotherapy in stage III non-small cell lung cancerPascale Tomasini, Laurent Greillier, Arnaud Boyer, et al.
Pageof 10